Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Fludarabine Phosphate

25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)

DRUG

Cyclophosphamide

250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)

DRUG

Rituximab

375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER